Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirikizumab - Eli Lilly and Company

Next Previous
Drug Profile

Mirikizumab - Eli Lilly and Company

Alternative Names: IL-23 antibody - Eli Lilly and Company; IL-23p19 antibody - Eli Lilly and Company; LY 3074828; Miri - Eli Lilly and Company; OMVOH; Omvoh

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies; Obesity therapies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis; Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ulcerative colitis
  • Registered Crohn's disease
  • Phase III Obesity
  • Discontinued Plaque psoriasis

Most Recent Events

  • 22 Sep 2025 Eli Lilly and Company plans the phase II TOPAZ-UC trial for Ulcerative colitis (Combination therapy, Monotherapy, Treatment-experienced) in Austria, Brazil, Canada, China, Denmark, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Romania, Spain, Turkey, USA (IV, SC), in November 2025 , (NCT07186101)
  • 15 Jul 2025 Efficacy data from the phase III VIVID-1 trial in Crohn's disease released by Eli Lilly and Company
  • 08 Jul 2025 Registered for Crohn's disease (In adults, Treatment-experienced) in Canada (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top